Haloperidol for treatment of cannabinoid hyperemesis syndrome

Hickey, Jami L.; Witsil, Joanne C.; Mycyk, Mark B.

doi:10.1016/j.ajem.2013.02.021

Cited by 71 publications

(60 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Secondary to intractable vomiting and high-temperature baths/showers, patients may present with moderate to severe dehydration and acute renal failure requiring aggressive fluid resuscitation [20,30,38,166]. In regard to symptomatic care, there is very limited evidence to support the use of dopamine antagonists [40,167]. For example, Hickey et al reported complete resolution of emesis 1 h after administration of 5 mg haloperidol to a CHS patient with intractable vomiting [40].…”

Section: Treatment Of Chsmentioning

confidence: 99%

“…In regard to symptomatic care, there is very limited evidence to support the use of dopamine antagonists [40,167]. For example, Hickey et al reported complete resolution of emesis 1 h after administration of 5 mg haloperidol to a CHS patient with intractable vomiting [40]. Δ9-THC has been shown to increase dopamine synthesis, turnover, efflux, and dopamine cell firing [103], which may explain clinical improvement with haloperidol treatment.…”

Section: Treatment Of Chsmentioning

confidence: 99%

See 1 more Smart Citation

Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment—a Systematic Review

et al. 2016

View full text Add to dashboard Cite

Cannabinoid hyperemesis syndrome (CHS) is a syndrome of cyclic vomiting associated with cannabis use. Our objective is to summarize the available evidence on CHS diagnosis, pathophysiology, and treatment. We performed a systematic review using MEDLINE, Ovid MEDLINE, Embase, Web of Science, and the Cochrane Library from January 2000 through September 24, 2015. Articles eligible for inclusion were evaluated using the G r a d i n g a n d R e c o m m e n d a t i o n s A s s e s s m e n t , Development, and Evaluation (GRADE) criteria. Data were abstracted from the articles and case reports and were combined in a cumulative synthesis. The frequency of identified diagnostic characteristics was calculated from the cumulative synthesis and evidence for pathophysiologic hypothesis as well as treatment options were evaluated using the GRADE criteria. The systematic search returned 2178 articles. After duplicates were removed, 1253 abstracts were reviewed and 183 were included. Fourteen diagnostic characteristics were identified, and the frequency of major characteristics was as follows: history of regular cannabis for any duration of time (100%), cyclic nausea and vomiting (100%), resolution of symptoms after stopping cannabis (96.8%), compulsive hot baths with symptom relief (92.3%), male predominance (72.9%), abdominal pain (85.1%), and at least weekly cannabis use (97.4%). The pathophysiology of CHS remains unclear with a dearth of research dedicated to investigating its underlying mechanism. Supportive care with intravenous fluids, dopamine antagonists, topical capsaicin cream, and avoidance of narcotic medications has shown some benefit in the acute setting. Cannabis cessation appears to be the best treatment. CHS is a cyclic vomiting syndrome, preceded by daily to weekly cannabis use, usually accompanied by symptom improvement with hot bathing, and resolution with cessation of cannabis. The pathophysiology underlying CHS is unclear. Cannabis cessation appears to be the best treatment

show abstract

Section: Treatment Of Chsmentioning

confidence: 99%

Section: Treatment Of Chsmentioning

confidence: 99%

Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment—a Systematic Review

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The persistent symptoms now need to be addressed. Williams & Wilkins, Inc. and Hickey et al (2013) identified a patient with CHS in their ED; initially, they treated him with a liter of saline, ondansetron (Zofran) 4 mg intravenously and a single dose of hydromorphone (Dilaudid) for his abdominal pain. All of his diagnostic laboratory results showed normal findings, and his symptoms persisted.…”

Section: Treatmentmentioning

confidence: 99%

“…Information in the literature from case studies is used as treatment guidelines (Hickey, Witsil, & Mycyk, 2013;Sun & Zimmerman, 2013). Guidelines to follow initially when treating CHS are to prevent dehydration, correct electrolyte deficiencies, and relieve the nausea, vomiting, and abdominal pain.…”

Section: Treatmentmentioning

confidence: 99%

Cannabinoid Hyperemesis Syndrome

Heise

2015

Advanced Emergency Nursing Journal

View full text Add to dashboard Cite

“…We would add our anecdotal success with sublingual olanzapine, which can obviate the need for IVaccess and allows for home treatment in some cases. Although case-based literature exists to support the use of anti-dopaminergic agents [2][3][4], there is clearly a need for controlled trials to definitively identify the most time and cost effective treatment approach. We welcome and support future collaboration towards this goal.…”

mentioning

confidence: 99%